Cherry Tree Wealth Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Cherry Tree Wealth Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-300	Closed	-$6.46K	–	585
2025 Q4	$6.46K	Buy	+300	New	+$5.82K	﹤0.01%	466

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cherry Tree Wealth Management's AVDL Position: Q1 2026 in Review

Cherry Tree Wealth Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 300 shares — an estimated $6.46K sold.

Cherry Tree Wealth Management first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $6.46K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Cherry Tree Wealth Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Cherry Tree Wealth Management sold 300 Avadel Pharmaceuticals shares in Q1 2026, an estimated $6.46K.
Cherry Tree Wealth Management first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Cherry Tree Wealth Management's Avadel Pharmaceuticals position peaked at $6.46K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Cherry Tree Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.